百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物

2014-05-29 fyc5078 DXY

5月27日,百时美施贵宝宣布与CytomX Therapeutics及Incyte达成一项专注于开发免疫肿瘤治疗药物的协议。百时美施贵宝首席科学官Francis Cuss评论称,“免疫肿瘤对改善癌症治疗方式提供了一个庞大的机遇,百时美施贵宝致力于推进我们免疫肿瘤药物的研究。”根据最初研究合作及许可协议(潜在价值达12亿美元),百时美施贵宝与CytomX将利用后者的Probody平台开发针对多种免疫

5月27日,百时美施贵宝宣布与CytomX Therapeutics及Incyte达成一项专注于开发免疫肿瘤治疗药物的协议。百时美施贵宝首席科学官Francis Cuss评论称,“免疫肿瘤对改善癌症治疗方式提供了一个庞大的机遇,百时美施贵宝致力于推进我们免疫肿瘤药物的研究。”


根据最初研究合作及许可协议(潜在价值达12亿美元),百时美施贵宝与CytomX将利用后者的Probody平台开发针对多种免疫肿瘤靶向治疗药物。两家公司指出,CytomX将赋予百时美施贵宝独家开发及上市Probodies平台包含CTLA-4在内的四款肿瘤靶点药物的全球权利。

作为协议的一部分,百时美施贵宝将向CytomX支持5000万美元的预付款,并提供研究资金。此外,CytomX有权获得临床前付款,及每款合作产品达2.98亿美元的未来开发、申报及销售里程碑付款,并有5%至10%左右的销售提成。

与此同时,百时美施贵宝将开展评价PD-1免疫检查点抑制剂试验药物Nivolumab与Incyte口服IDO1抑制剂INCB24360合并用药的情况。两家公司指出,一项用于多种肿瘤类型的1/2期研究正计划于第四季度启动,这项试验将由两家公司共同投资和实施。进一步的协议细节未披露。

据百时美施贵宝与Incyte提供的信息,临床前证据表明,Nivolumab与INCB24360的合并用药与两种药物的单独用药相比,可能导致一种增强的抗肿瘤免疫响应。

5月初,Incyte与阿斯利康MedImmune单元在一项INCB24360与后者抗PD-L1免疫检查点抑制剂MEDI4736合并用药的1/2期研究上展开合作。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
    2014-11-20 jktdtl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
    2014-05-31 zhouqu_8
  6. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1741115, encodeId=b3191e411153e, content=<a href='/topic/show?id=90e929150a0' target=_blank style='color:#2F92EE;'>#免疫肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29150, encryptionId=90e929150a0, topicName=免疫肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16134864193, createdName=ms6323715314570549, createdTime=Sat Feb 28 17:36:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764431, encodeId=f7691e644313a, content=<a href='/topic/show?id=8fe0e188265' target=_blank style='color:#2F92EE;'>#百时美#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71882, encryptionId=8fe0e188265, topicName=百时美)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9b037737594, createdName=ms1467340776200723, createdTime=Wed Feb 18 04:36:00 CST 2015, time=2015-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685270, encodeId=032a16852e0ec, content=<a href='/topic/show?id=03135881224' target=_blank style='color:#2F92EE;'>#施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58812, encryptionId=03135881224, topicName=施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=394828104279, createdName=jktdtl, createdTime=Thu Nov 20 04:36:00 CST 2014, time=2014-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71883, encryptionId=43abe1883b6, topicName=百时美施贵宝)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439315, encodeId=1a781439315a8, content=<a href='/topic/show?id=7f269824dc' target=_blank style='color:#2F92EE;'>#Incyte#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9824, encryptionId=7f269824dc, topicName=Incyte)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446744, encodeId=e1191446e4482, content=<a href='/topic/show?id=94bd830865e' target=_blank style='color:#2F92EE;'>#肿瘤药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83086, encryptionId=94bd830865e, topicName=肿瘤药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKneTxOtx0KRAPibib3sfmib4P2269UG6op6ZN5ZKddPvUibR7RfFob8X6FicRugoeY8Dicy4cibArjj168Q/132, createdBy=c17d5287383, createdName=smartjoy, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537660, encodeId=ba6c153e660d5, content=<a href='/topic/show?id=1f9983082fa' target=_blank style='color:#2F92EE;'>#肿瘤药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83082, encryptionId=1f9983082fa, topicName=肿瘤药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed1012894470, createdName=30397608, createdTime=Sat May 31 01:36:00 CST 2014, time=2014-05-31, status=1, ipAttribution=)]

相关资讯

百时美施贵宝25亿美元收购丙肝药商Inhibitex

北京时间1月9日上午消息,据外电报道,百时美施贵宝公司(Bristol-Myers Squibb Co)日前同意斥资约25亿美元现金收购丙型肝炎药物开发商Inhibitex,这是该公司在短短两个月内收购的第二家专门从事丙肝药物研发的公司。 1月8日,Inhibitex在声明中称,他们将向股东建议接受百时美施贵宝的每股26美元报价,这一价格比该公司在1月6日的收盘价9.87美元高出一倍以上。 此

华法林时代终结了吗?抗凝药如何选?

    去年12月28日,FDA批准阿哌沙班 (Eliquis,百时美施贵宝/辉瑞)用于非瓣膜性房颤(AF) 患者卒中和全身性栓塞的预防。随着多数大国批准阿哌沙班用于非瓣膜性心房颤动(AF)患者的卒中和系统性栓塞预防,现在,3种新口服抗凝药将全数用于该症,从而使医生在患者和药物的选择上无所适从。但是,这些药物真的会宣告华法林的终结吗?医生该如何决定选用哪种药呢?&nb